Farhad Ravandi, MD

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Farhad Ravandi, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance in adults with acute myeloid leukemia.